{"prompt": "['OSTPDL1', 'Page 25 of 60', 'Any Grade 3 ADRs require treatment discontinuation with avelumab except for', 'any of the following:', 'Transient (< 6 hours) Grade 3 flu-like symptoms or fever, which is controlled', 'with medical management', 'Transient (< 24 hours) Grade 3 fatigue, local reactions, headache, nausea,', 'emesis that resolves to Grade < 1', 'Single laboratory values out of normal range (excluding Grade 3 liver function', 'test increase) that are unlikely related to study treatment according to the', 'Investigator, do not have any clinical correlate, and resolve to Grade < 1 within', '7 days with adequate medical management', 'Tumor flare phenomenon defined as local pain, irritation, or rash localized at', 'sites of known or suspected tumor', 'Grade 3 rash that resolves to Grade 1 with steroid treatment', 'Change in ECOG PS to 3 that does not resolve to \u00a3 2 within 14 days (infusions', 'should not be given on the following cycle, if the ECOG PS is 3 on the day of', 'study drug administration)', 'Any Grade 2 ADR should be managed as follows:', 'If a Grade 2 ADR resolves to Grade < 1 by the last day of the current cycle,', 'treatment may continue.', 'Upon the second occurrence of the same Grade 2 ADR (except for hormone', 'insufficiencies that can be managed by replacement therapy) in the same', 'participant, treatment with avelumab has to be permanently discontinued.', 'St. Jude', 'IRB NUMBER: Pro00006856', 'Revision 1.1, dated: 01-19-2018', 'IRB approved: 01-26-3018 APPROVAL DATE: 06/26/2019', 'Protocol document dated: 01-19-2018']['OSTPDL1', 'Page 26 of 60', '5.2 Treatment Modification for Symptoms of Infusion-Related', 'Reactions', 'In order to mitigate infusion-related reactions, all participants will receive', 'pretreatment with H1 blockers and acetaminophen 30 to 60 minutes', 'prior to each infusion. A premedication regimen of 1 mg/kg', 'diphenhydramine (MAX 50 mg) and 10-15mg/kg acetaminophen (MAX', '1000 mg) is recommended prior to each dose of drug. Participants must', 'be observed for 2 hours post-infusion. This regimen may be modified', 'based on local treatment standards and guidelines as appropriate.', 'NCI-CTCAE Grade', 'Treatment Modification for Study', 'Drug', 'Grade 1 - mild', 'Decrease the study drug infusion', 'Mild transient reaction; infusion', 'rate by 50% and monitor closely for', 'interruption not indicated;', 'any worsening.', 'intervention not indicated.', 'The total infusion time for study', 'drug should not exceed', '120 minutes.', 'Grade 2 - moderate', 'Stop study drug infusion.', 'Therapy or infusion interruption', 'Resume infusion at 50% of previous', 'indicated but responds promptly to', 'rate once infusion-related reaction', 'symptomatic treatment (for', 'has resolved or decreased to at least', 'example, antihistamines, NSAIDs,', 'Grade 1 in severity, and monitor', 'narcotics, IV fluids); prophylactic', 'closely for any worsening.', 'medications indicated for \u00a3 24 h.', 'Grade 3 or Grade 4 - severe or', 'Stop the study drug infusion', 'life-threatening', 'immediately and disconnect infusion', 'Grade 3: Prolonged (for example,', 'tubing from the participant.', 'not rapidly responsive to', 'Participants have to be withdrawn', 'symptomatic medication and/or', 'immediately from study drug', 'brief interruption of infusion);', 'treatment and must not receive any', 'recurrence of symptoms following', 'further study drug treatment.', 'initial improvement; hospitalization', 'indicated for clinical sequelae.', 'Grade 4: Life-threatening', 'consequences; urgent intervention', 'indicated.', 'Once the avelumab infusion rate has been decreased by 50% or', 'interrupted due to an infusion-related reaction, it must remain', 'decreased for all subsequent infusions.', 'If the patient has a second infusion-related reaction Grade 2 on the', 'slower infusion rate, the infusion should be stopped and the patient', 'should be removed from study treatment.', 'If hypersensitivity reaction occurs, the patient must be treated according', 'to the best available medical practice.', 'St. Jude', 'IRB NUMBER: Pro00006856', 'Revision 1.1, dated: 01-19-2018', 'IRB approved: APPROVAL DATE: 06/26/2019', 'Protocol document dated: 01-19-2018']['OSTPDL1', 'Page 27 of 60', 'St. Jude', 'IRB NUMBER: Pro00006856', 'Revision 1.1, dated: 01-19-2018', 'IRB approved: DATE: 06/26/2019', 'Protocol document dated: 01-19-2018']\n\n###\n\n", "completion": "END"}